Innexus Biotechnologies

Category: Drugs & Pharmaceuticals

InNexus Biotechnology, Inc. is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL) improving the potency of existing antibody products while opening new markets and disease applications.

Pipeline

The company's two compounds in preclinical development are 1) DXL625 (CD20) for the treatment of non-Hodgkin's lymphoma (NHL) and 2) DXL702 (HER2/neu), for the treatment of breast cancer.

DXL625 (CD20) will serve the same market as Rituxan. Genentech, Inc. and Biogen IDEC developed Rituxan, which generates billions of USDs in annual sales.

DXL702 (HER2/neu), will serve the same market as Herceptin, which was also developed by Genentech, Inc. and is also a multi-billion dollar success.

We are advancing both of our compounds toward the Food and Drug Administration with preclinical programs. We are determined to show market leadership by bringing these new products to the marketplace.